A Phase 1 interventional study of MK0683, vorinostat in Neoplasms, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung — none open to participants now, 1 under way, none of them phase 3. Vorinostat · Carcinoma, Non-Small-Cell Lung.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2007, is one of 11 in phase 1, and was the 7th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →None of the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung is open now. The open studies under Carcinoma, Non-Small-Cell Lung, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 9 · Phase 3 1
First in 2001; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 21 across the 19 interventional studies. Of the 18 that completed or were terminated, 11 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc: 14 open now, 26 under way, 18 of them phase 3. Of 65 finished, 49 (75%) have results posted.
Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 88th largest by enrollment of the 88 interventional ones that give a count, is one of 4 that started in 2007, is one of 19 in phase 1, and was the 11th registered.
Merck & Co., Inc’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 91 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The clinical study will evaluate safety, tolerability and Pharmacokinetics of MK0683 in combination with carboplatin and paclitaxel in chemotherapy-naive NSCLC patients.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
This study's enrollment of 3 is below the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Compared within Carcinoma, Non-Small-Cell Lung, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
Also known as: MK0683
Number of Participants With a Dose Limited Toxicity at First Cycle
Dose Limited Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment.
Time frame: 25 Days (first cycle)
Area Under the Curve (AUC(0-24 hr)) at Day 4
Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.
Time frame: Day 4
Area Under the Curve (AUC(0-24 hr)) at Day 5
Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.
Time frame: Day 5
Maximum Concentration (Cmax) at Day 4
Maximum Concentration (Cmax) = the maximum plasma concentration of the drug
Time frame: Day 4
Maximum Concentration (Cmax) at Day 5
Maximum Concentration (Cmax) = the maximum plasma concentration of the drug
Time frame: Day 5
Date of first participant in: 26 January 2007. Data of last participant's last visit in study protocol: 7 March 2007. The study was conducted at single center in Japan.
| Milestone | Vorinostat (300 mg) | Vorinostat (400 mg) |
|---|---|---|
| Started | 3 | 0 |
| Completed | 0 | 0 |
| Not completed | 3 | 0 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 |
Dose Limited Toxicity = Drug-related side effects that are serious enough to prevent an increase in dose or level of that treatment.
| Participants | Vorinostat (300 mg) |
|---|---|
| Number of Participants With a Dose Limited Toxicity at First Cycle | 3 |
Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.
| µM hr | Vorinostat (300 mg) |
|---|---|
| Area Under the Curve (AUC(0-24 hr)) at Day 4 | 9.76 (6.61 to 12.90) |
Area Under the Curve (AUC (0-24 hr)) = Area under the plasma concentration versus time curve (AUC) from time zero to 24 hour.
| µM hr | Vorinostat (300 mg) |
|---|---|
| Area Under the Curve (AUC(0-24 hr)) at Day 5 | 6.26 (5.37 to 7.14) |
Maximum Concentration (Cmax) = the maximum plasma concentration of the drug
| µM | Vorinostat (300 mg) |
|---|---|
| Maximum Concentration (Cmax) at Day 4 | 1.54 (0.99 to 2.09) |
Maximum Concentration (Cmax) = the maximum plasma concentration of the drug
| µM | Vorinostat (300 mg) |
|---|---|
| Maximum Concentration (Cmax) at Day 5 | 1.96 (1.60 to 2.32) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat (300 mg) | — | 0/3 (0%) | — |
| Event | Vorinostat (300 mg) |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 2/3 |
| LeukopeniaBlood and lymphatic system disorders | 2/3 |
| LymphopeniaBlood and lymphatic system disorders | 2/3 |
| DiarrhoeaGastrointestinal disorders | 2/3 |
| NauseaGastrointestinal disorders | 2/3 |
| VomitingGastrointestinal disorders | 2/3 |
| FatigueGeneral disorders | 2/3 |
| PyrexiaGeneral disorders | 2/3 |
| AnorexiaMetabolism and nutrition disorders | 2/3 |
| Neutrophil count decreasedInvestigations | 2/3 |
| Age, Continuous(years) | Vorinostat (300 mg) |
|---|---|
| Mean | 64 ± 2.0 |
| Sex: Female, Male(Participants) | Vorinostat (300 mg) |
|---|---|
| Female | 1 |
| Male | 2 |
No study locations are listed for this record.
The record gives a start of Jan 2007, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2009, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat
Carcinoma, Non-Small-Cell Lung →